AURKB and small cell lung carcinoma: BCL2 inhibitors such as venetoclax [110], navitoclax (NCT03366103) [111], oblimersen sodium (G31399) [112], and palcitoclax (NCT03366103) show modest results when combined with other therapies [113], and enhance sensitivity to AURKB inhibition in pre-clinical SCLC models [114].